Editorial Message and Issue Highlights –Vol. 15, No. 5–6, May-June 2018

Dear Colleagues: Welcome to the May–June 2018 issue of Innovations in Clinical Neuroscience (ICNS). We start the issue with a timely review article by Touma and Scarff titled, “Valbenazine and Deutetrabenazine for Tardive Dyskinesia (TD).” Here, the authors discuss the two drugs, which were recently approved by the United States Food and Drug Administration (FDA) for the treatment of TD. The authors describe the drugs’ unique mechanisms of action as well as the evidence supporting their efficacy, tolerability, dosing, drug interactions, and precautions. Next, in the article titled “Combination Phentermine–Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study,” Guerdjikova et al present preliminary data regarding the usefulness of the combination of phentermine and topiramate extended release (phentermine–topiramate [Qsymia®, Vivus, Inc.]) for treatment of binge eating disorder (BED) associated with obesity or overweight. The researchers report that phentermine–topiramate treatment was associated with significant reductions in weight, body mass index, binge eating episode frequency and measures of global clinical severity, eating disorder psychopathology, and obsessive-compulsive symptoms among their very small patient sample. The authors acknowledge that controlled studies with larger patient samples are needed to confirm these preliminary results. Following this, Sheehan et al present data on the effects ...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Editor's Message: Issue Highlights Editorial Message Source Type: research